Allison M. Bock
( out of 14 reviews )

Allison M. Bock, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626

  • Dr. Allison Bock is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies. She specializes in treating patients with lymphoma and chronic lymphocytic leukemia. She completed her Internal Medicine residency training at the University of Colorado and fellowship training in Hematology/Oncology at the Mayo Clinic in Rochester, MN. Her research focuses on improving outcomes for patients with lymphomas through the development of clinical trials with novel therapies and investigation of prognostic/predictive biomarkers including biological pathways and mechanisms that lead to therapy resistance. She is the principal investigator on multiple lymphoma clinical trials at Huntsman Cancer Institute, including an investigator-initiated randomized phase 2 study evaluating a bispecific antibody therapy for patients at high risk of relapse post CAR-T. She is also an active participant within the national Southwest Oncology Group. She has medical licensure in the states of UT, WY, MT, and ID in order to provide better access to care for the rural communities HCI serves.

    For questions regarding Dr. Bock's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at (801) 585-6906.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    5.0 /5
    ( out of 14 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 31, 2024
    HUNTSMAN CANCER CENTER

    She is very knowledgeable, professional, and kind. She takes time to answer all my questions and is very patient.

    October 05, 2024
    HUNTSMAN CANCER CENTER

    Very competent and knowledgeable. Personable and understanding of the specific cancer and questions about diagnosis and treatment options.

    September 10, 2024
    HUNTSMAN CANCER CENTER

    I am very pleased with the care I am receiving from Allison Bock and would recommend her to anyone who could benefit from her care.

    September 05, 2024
    HUNTSMAN CANCER CENTER

    Dr. Bock and her team clearly and effectively explained my disease characteristics and treatment possibilities, making technical aspects of both very understandable. I have high confidence that she provides excellent care. This was important for me and my family facing a very recent cancer diagnosis.

    June 26, 2024
    HUNTSMAN CANCER CENTER

    Interested, helpful, and very knowledgeable.

    June 22, 2024
    HUNTSMAN CANCER CENTER

    Dr. Bock is a very caring, knowledgeable physician. She takes time to listen and to make helpful suggestions. I'm so glad I found her.

    May 22, 2024
    HUNTSMAN CANCER CENTER

    Dr. Bock is a very thorough and thoughtful doctor. My experience with her all the way through treatment for DLBCL has been excellent. She and her staff were very responsive to my needs and communication was constant. Cannot recommend her highly enough.

    May 03, 2024
    HUNTSMAN CANCER CENTER

    Dr. Bock is extremely knowledgeable and takes time to answer questions. I'm in good hands.

    April 17, 2024
    HUNTSMAN CANCER CENTER

    Dr. Bock is both professional and friendly and actually listens and discusses options. She treated me as an equal in my care. I will continue any future medical care with her.

    See More Patient Comments

  • Dr. Allison Bock is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies. She specializes in treating patients with lymphoma and chronic lymphocytic leukemia. She completed her Internal Medicine residency training at the University of Colorado and fellowship training in Hematology/Oncology at the Mayo Clinic in Rochester, MN. Her research focuses on improving outcomes for patients with lymphomas through the development of clinical trials with novel therapies and investigation of prognostic/predictive biomarkers including biological pathways and mechanisms that lead to therapy resistance. She is the principal investigator on multiple lymphoma clinical trials at Huntsman Cancer Institute, including an investigator-initiated randomized phase 2 study evaluating a bispecific antibody therapy for patients at high risk of relapse post CAR-T. She is also an active participant within the national Southwest Oncology Group. She has medical licensure in the states of UT, WY, MT, and ID in order to provide better access to care for the rural communities HCI serves.

    For questions regarding Dr. Bock's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at (801) 585-6906.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology - Mayo Clinic Fellow
    Internal Medicine - University of Colorado School of Medicine Resident
    Professional Medical Medicine; Global Health Pathway - Medical College of Wisconsin M.D.
    Genetics, Cell Biology and Development; minor in Psychology - University of Minnesota - Twin Cities B.S.

    Selected Publications

    Journal Article

    1. Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton MR, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein PG, Chaudhry A, Olszewski AJ (2024). High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series. Blood Adv, 8(20), 5355-5364. (Read full article)
    2. Okcu I, Wang Y, Bock AM, Zhou J, Moustafa MA, Tun HW, Rosenthal AC, Johnston PB, Baidoun F, Khurana A, Kabat BF, King RL, Habermann TM, Nowakowski GS (2024). Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis. Clin Lymphoma Myeloma Leuk.
    3. Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, Kahl BS, Martin P, Cohen JB, Casulo C, Lossos IS, Farooq U, Ayyappan S, Reicks TW, Habermann TM, Witzig TE, Flowers CR, Cerhan JR, Nastoupil LJ, Nowakowski GS (2024). Defining Primary Refractory Large B-cell Lymphoma. Blood Adv. (Read full article)
    4. Wenzl K, Stokes ME, Novak JP, Bock AM, Khan S, Hopper MA, Krull JE, Dropik AR, Walker JS, Sarangi V, Mwangi R, Ortiz M, Stong N, Huang CC, Maurer MJ, Rimsza L, Link BK, Slager SL, Asmann Y, Mondello P, Morin R, Ansell SM, Habermann TM, Witzig TE, Feldman AL, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak AJ (2024). Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL. Blood Cancer J, 14(1), 100. (Read full article)
    5. Hines AS, Koster MJ, Bock AR, Go RS, Warrington KJ, Olteanu H, Lasho TL, Patnaik MM, Reichard KK (2022). Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome. Rheumatology (Oxford), 62(12), 3947-3951. (Read full article)
    6. Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski AJ (2023). High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv, 7(21), 6381-6394. (Read full article)
    7. Bock AM, Gile JJ, Larson MC, Poonsombudlert K, Tawfiq RK, Maliske S, Maurer MJ, Kabat BF, Paludo J, Inwards DJ, Ayyappan S, Link BK, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS, Cerhan JR, Farooq U, Wang Y (2023). Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer J, 13(1), 169. (Read full article)
    8. Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz J, Borate U, Wilmot B, Tognon C, Bock AM, Pollyea DA, Radhakrishnan S, Radhakrishnan S, Patel P, Collins RH, Tantravahi S, Deininger MW, Fan G, Druker B, Shinde U, Tyner JW, Press RD, McWeeney S, Agarwal A (2021). Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood, 139(8), 1208-1221. (Read full article)
    9. Simpson HM, Bock A, Cervantes L (2021). Policy in clinical practice: Emergency Medicaid and access to allogeneic stem cell transplant for undocumented immigrants. J Hosp Med, 17(1), 50-53. (Read full article)
    10. Canfield GS, Bock A, Mann S, Zimmer S, Somerset H, Franco-Paredes C, Wilson CC, Metter RB (2020). A 31-year-old Micronesian Man With Shoulder Fungating Mass. Clin Infect Dis, 70(5), 973-975. (Read full article)
    11. Bock AM, Brunmeier A, Wichman CL, Bergl PA (2017). Encephalopathy With Psychosis Following Group A Streptococcal Sepsis-An Immune-Mediated Phenomenon? Psychosomatics, 58(5), 551-555. (Read full article)
    12. Bock AM, LeVeque M, Camitta B, Talano JA (2016). Successful treatment of recurrent CNS disease post-bone marrow transplant in children with familial hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer, 63(12), 2154-2158. (Read full article)
    13. Bock A, Chintamaneni K, Rein L, Frazer T, Kayastha G, MacKinney T (2016). Improving pneumococcal vaccination rates of medical inpatients in urban Nepal using quality improvement measures. BMJ Qual Improv Rep, 5(1). (Read full article)
    14. Knorr DA, Bock A, Brentjens RJ, Kaufman DS (2013). Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy. Stem Cells Dev, 22(13), 1861-9. (Read full article)
    15. Bock AM, Knorr D, Kaufman DS (2013). Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs). J Vis Exp, (74), e50337. (Read full article)
    16. Bock AM, Cao Q, Ferrieri P, Young JA, Weisdorf DJ (2012). Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. Biol Blood Marrow Transplant, 19(1), 102-8. (Read full article)

    Review

    1. Bock AM, Nowakowski GS, Wang Y (2022). Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. [Review]. Curr Treat Options Oncol, 23(2), 155-170. (Read full article)

    Letter

    1. Ng WL, Wang Y, Bock AM, Jevremovic D, Wang ML, Nowakowski GS (2023). Review of management options for mantle cell lymphoma in pregnancy. [Letter to the editor]. Leuk Lymphoma, 64(6), 1194-1198. (Read full article)
    2. Bock AM, Pollyea DA (2020). Venetoclax with azacitidine for two younger Jehovah's Witness patients with high risk acute myeloid leukemia. [Letter to the editor]. Am J Hematol. (Read full article)